← The record

Amino Acid Formula With Carbohydrate, Vitamins, Minerals And Trace Elements Without Phenylalanine, Supplemented With Docosahexaenoic Acid

Not recommended MetabolicNot applicableNot applicable line

Dietary management of phenylketonuria (PKU) or hyperphenylalaninaemia in children from 10 years of age or adults.

2
Submissions
1 resub
2017–20
On the record
ICER range
Not modelled
Cost basis

Access path

2 submissions · public record
  1. Nov 2017
    Not recommended

    lack of clinical data to indicate clinical need, absence of copper and inadequate phosphorus levels (essential…

  2. Jul 2020
    Not recommended

    No clinical need for the product; other products with better nutritional profiles available; product does not provide…

RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
8.1 The PBAC did not recommend the listing of PKU Synergy for the dietary management of phenylketonuria (PKU) or hyperphenylalaninaemia in children from 10 years of age.PSD · Jul 2020
The PBAC maintained its previous view that there were other products with better nutritional profiles for this patient population and that there was no clinical need for this product.PSD · Jul 2020
Clinical claim
5.6 The sponsor claimed that the study demonstrated that reintroducing a low volume, nutrient enriched protein substitute (PKU Synergy) at 1 sachet 33 g per day, delivered favourable nutritional results and potential mood benefits in non-compliant PKU patients. The sponsor also claimed that the study demonstrated no deficiencies in copper, phosphorous, vitamin B6, folate, biotin and niacin.PSD · Jul 2020
5.7 The sponsor maintained that PKU Synergy will enable patients who are non-compliant in their dietary therapy and patients with a higher tolerance to phenylalanine, to meet micronutrient requirements in a smaller volume of product, which may result in less wastage of current protein substitute (prescriptions), savings to the PBS and potentially better patient compliance. Pricing considerationsPSD · Jul 2020
Consumer comments
5.5 The sponsor noted that the study reported at days 1-3 of the study, natural protein intake and estimated Phenylalanine were high with low intakes of calcium, magnesium, iron, zinc, iodine and Vitamin D. The sponsor noted that after intervention (day 29-31) with PKU Synergy, the following results were reported: 3PSD · Jul 2020

Cost-effectiveness

Not modelled; this is a nutritional product submission without economic evaluation of cost-effectiveness.

As a minor submission, the financial estimates have not been independently evaluated. PBAC · 2020

Decision context

PopulationChildren from 10 years of age and adults with phenylketonuria (PKU) or hyperphenylalaninaemia, particularly those non-compliant with dietary therapy or with higher tolerance to phenylalanine.

Why it was knocked back

  • No clinical need for the product; other products with better nutritional profiles available; product does not provide adequate copper and phosphorus for patients on a relaxed diet; insufficient evidence of additional benefits compared to PBS-listed alternatives; recommended dosing (one sachet per day) may be confusing to patients; inadequate clinical evidence from single small study of short duration

Submission history

2 entries
DecidedOutcomeComparatorICEREvidence
Jul 2020 Not recommended PKU Express 20®, PKU Lophlex® Single-arm · Eating behaviour, nutrient intake, mood
Nov 2017 Not recommended PKU Express 20, Lophlex Cost-minimisation · Cost-minimisation

Similar precedents

By decision profile